Opiant Pharmaceuticals (NASDAQ: OPNT) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Volatility and Risk

Opiant Pharmaceuticals has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.

Earnings & Valuation

This table compares Opiant Pharmaceuticals and Catalyst Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million 4.71 $5.99 million $2.54 13.70
Catalyst Biosciences $561,999.00 38.88 -$19.79 million ($17.78) -0.29

Opiant Pharmaceuticals has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

29.2% of Catalyst Biosciences shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Catalyst Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Opiant Pharmaceuticals and Catalyst Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Catalyst Biosciences 0 0 3 0 3.00

Catalyst Biosciences has a consensus target price of $24.50, indicating a potential upside of 383.23%. Given Catalyst Biosciences’ higher possible upside, analysts plainly believe Catalyst Biosciences is more favorable than Opiant Pharmaceuticals.

Profitability

This table compares Opiant Pharmaceuticals and Catalyst Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%
Catalyst Biosciences -3,127.92% -92.61% -46.69%

Summary

Opiant Pharmaceuticals beats Catalyst Biosciences on 7 of the 12 factors compared between the two stocks.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

About Catalyst Biosciences

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Receive News & Stock Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.